Consensus estimates for Heron Therapeutics anticipate a Q2 2026 loss of $0.02 per share on revenue of $42.19 million, with the stock currently trading near $0.50 against a bullish average analyst price target of $2.00.
Investors are primarily focused on the commercial traction of the Acute Care franchise, specifically the unit demand growth for ZYNRELEF and APONVIE following recent sales force expansions and reimbursement improvements.
Recent performance highlights a strategic shift toward the higher-growth Acute Care segment, which saw 32% year-over-year revenue growth in the previous quarter despite seasonal headwinds.
Management has reaffirmed its full-year 2026 guidance, targeting positive Adjusted EBITDA between $10 million and $20 million, signaling that the company is approaching a critical operational profitability inflection point.